Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BetterLife Pharma Inc BETRF


Primary Symbol: C.BETR

Healthcare
BetterLife Pharma Inc. is a biotechnology company. The Company is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and is a non-hallucinogenic and non- controlled lysergic acid diethylamide (LSD) derivative in development and that is unregulated and therefore can be... see more

Recent & Breaking News (CSE:BETR)

BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001

GlobeNewswire October 23, 2024

BetterLife Announces Fully Subscribed Private Placement Financing

GlobeNewswire August 29, 2024

BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent

GlobeNewswire August 27, 2024

Amendment of Disclosures in Past Management Information Circulars

GlobeNewswire July 16, 2024

BetterLife Announces Closing of a Private Placement

GlobeNewswire July 2, 2024

BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria

GlobeNewswire June 26, 2024

BetterLife Announces Closing of a Private Placement

GlobeNewswire June 14, 2024

BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001

GlobeNewswire May 14, 2024

BetterLife Announces Intent to Complete Private Placement of Units

GlobeNewswire May 3, 2024

BetterLife Advances BETR-001 IND-enabling Studies

GlobeNewswire May 1, 2024

BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Newsfile April 15, 2024

BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 11, 2024

BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001

GlobeNewswire April 3, 2024

BetterLife's 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University

GlobeNewswire March 4, 2024

BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001

GlobeNewswire January 2, 2024

BetterLife Announces Closing of a Private Placement

GlobeNewswire December 18, 2023

BetterLife Announces Extension of Warrants

GlobeNewswire November 30, 2023

US Patent and Trademark Office Publishes BetterLife's Comprehensive Patent for BETR-001 and Other LSD Derivatives

GlobeNewswire November 15, 2023

BetterLife Pharma to Host Investors Update Call on September 18, 2023

GlobeNewswire September 14, 2023

BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001

GlobeNewswire September 12, 2023